Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A

Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A

SSSE:603392
22.20
CNY
-0.29
(-1.29%)
-0.36EPS
34.57BMarket Cap
Mar 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.51
0.58
0.66
0.82
0.93
0.92
1.08
1.97
4.67
8.95
4.37
1.69
1.42
1.49
Basic EPS, GAAP
0.08
0.12
0.12
0.14
0.15
0.27
0.19
0.57
1.64
3.79
0.99
0.08
-0.31
-0.35
Free Cash Flow per Basic Share
- -
- -
- -
- -
-0.07
-0.04
0.1
0.07
0.52
2.56
0.3
-0.4
-0.56
- -
Dividend per Share
0.02
- -
0.1
- -
- -
0.01
- -
- -
0.09
0.1
0.72
0.31
- -
- -
Book Value per Share
0.37
0.57
0.67
0.87
0.86
1.22
1.41
2.07
3.62
9.73
10.01
9.69
9.38
9.2
Tangible Book Value per Share
0.32
0.51
0.48
0.61
0.6
0.99
1.19
1.88
3.38
9.47
9.51
9.13
8.62
8.38
Basic Weighted Avg Shares
986
1,020
1,028
1,027
1,018
1,068
1,099
1,195
1,230
1,250
1,260
1,328
1,285
1,306
Sales/Revenue/Turnover
499
596
681
844
950
983
1,184
2,354
5,750
11,185
5,511
2,245
1,819
1,943
Operating Margin (%)
21.97
21.34
18.33
15.44
20.04
17.49
18.69
35.07
42.37
50.06
29.43
0.1
-23.44
-19.2
Depreciation Expense
- -
- -
- -
- -
42
71
81
84
105
152
232
301
346
- -
Net Income, GAAP
80
118
119
148
150
293
209
677
2,021
4,736
1,248
106
-398
-456
Effective Tax Rate (%)
22.62
11.79
18.78
13.9
15.79
- -
3
10.81
10.54
12.89
10.54
- -
- -
- -
Profit Margin (%)
16
19.87
17.53
17.56
15.84
29.82
17.64
28.76
35.15
42.34
22.64
4.73
-21.9
-23.45
Working Capital
186
332
281
233
189
526
394
1,144
2,281
8,695
7,632
6,363
5,724
5,113
LT Debt
- -
- -
- -
- -
118
21
21
18
37
121
128
175
144
168
Total Equity
382
580
723
960
899
1,370
1,581
2,580
4,562
12,565
12,884
12,448
12,033
11,801
Return on Invested Capital (%)
- -
19.41
14.56
13.27
14.47
- -
14.15
32.51
55.02
55.11
9.72
- -
- -
- -
Return on Capital (%)
- -
23.01
19.96
19.05
14.88
- -
13.93
31.46
52.29
52.17
9.64
- -
- -
- -
Return on Common Equity (%)
- -
24.62
18.79
18.77
17.02
26.3
14.36
32.92
57.59
56.35
9.96
0.85
-3.3
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
249
179
175
LT Borrowings
59
88
120
LT Finance Leases
47
56
48
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,264
1,264
1,264
Market Capitalization
50,260
34,101
34,568

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
6,731
6,744
6,638
Cash, Cash Equivalents & STI
3,961
3,940
3,922
Accounts Receivable, Net
1,501
1,509
1,519
Inventories
767
773
750
Total Current Liabilities
1,598
1,594
1,525
Payables & Accruals
- -
- -
- -
ST Debt
249
179
175
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.55%
49.61%
-3.33%
Free Cash Flow
- -
165.18%
34.41%
Net Income, GAAP
0.87%
-61.43%
-474.89%
Sales/Revenue/Turnover
26.91%
21.96%
-18.99%
Total Cash Common Dividend
- -
1,437.58%
-99.44%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
753
614
582
297
2,245
2025
401
443
- -
321
1,819
2026
523
525
574
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.11
- -
-0.13
0.08
2025
-0.04
-0.07
- -
-0.18
-0.31
2026
-0.03
-0.07
-0.08
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.33
- -
- -
0.31
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Zi Xin Qiu
Full Time Employees
4,116
Sector
Health technology
Industry
Biotechnology
Address
No. 31 Kexueyuan Road Beijing BE China 102206
IPO Date
Apr 3, 2020
Website
ystwt.com
Business
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS) is a China-based biopharmaceutical company that researches, develops, produces, distributes, and sells in vitro diagnostic reagents and instruments, as well as vaccines, primarily targeting infectious diseases such as HIV, hepatitis viruses (A, B, C, D, E), tuberculosis, syphilis, HPV, influenza A/B, and nasopharyngeal cancer. Its core diagnostic products encompass chemiluminescence immunoassay kits, ELISA kits, colloidal gold rapid tests, nucleic acid extraction and detection systems (including WanTag series, MFCS-6, FMNE-08), molecular diagnostics, bioactive materials (over 300 antigens, antibodies, core enzymes via subsidiary Innobiomax), quality control products (over 150 reference materials), and automated analyzers like Wan600, Wan BC2800, WanTLA for chemiluminescence and biochemistry testing with a menu of 220 assays; vaccine portfolio includes the world's first recombinant hepatitis E vaccine (Hecolin®), bivalent HPV vaccine (Cecolin®, WHO prequalified), nine-valent HPV vaccine (launched in China in 2025), and nasal spray COVID-19 vaccine (Pneucolin®), all developed using proprietary E. coli recombinant virus-like particle technology in collaboration with the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD). Founded in 1991 and headquartered at No. 31 Science Park Road, Changping District, Beijing, China, the company operates principally in China with international distribution of diagnostics and vaccines, serving healthcare providers, blood banks, disease control centers, clinical labs, and third-party testing facilities through segments in diagnostics (including core and innovative solutions like intelligent labs, chronic disease management, women's health programs) and vaccines. Recent developments include the 2025 launch of China's first domestically produced nine-valent HPV vaccine, a strategic partnership with Hoyotek Biomedical Co., Ltd. for enhanced biomedical capabilities, completion of share repurchases with partial cancellation announced in October 2025, winning the China Patent Gold Award in June 2025, and participation in global events like Malaysia WHX Labs 2025, alongside ongoing advancements in bioactive materials self-sufficiency (80%) and innovative assays such as Hepatitis E urine tests, IL-6, HIV 4th generation CLIA, and TB-IGRA for population screening.